The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter randomized phase III trial of nonpegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide (MC) versus liposome-encapsulated doxorubicin citrate plus vinorelbine (MV) as first-line treatment in locally advanced (LABC) or metastatic breast cancer (MBC).
V. Lorusso
No relevant relationships to disclose
F. Giotta
No relevant relationships to disclose
R. Bordonaro
No relevant relationships to disclose
E. Maiello
No relevant relationships to disclose
S. Del Prete
No relevant relationships to disclose
V. Gebbia
No relevant relationships to disclose
G. Filippelli
No relevant relationships to disclose
S. Pisconti
No relevant relationships to disclose
S. Cinieri
No relevant relationships to disclose
S. Romito
No relevant relationships to disclose
F. Riccardi
No relevant relationships to disclose
G. Cairo
No relevant relationships to disclose
V. E. Chiuri
No relevant relationships to disclose
M. Ciccarese
No relevant relationships to disclose
R. Forcignano
No relevant relationships to disclose
L. Petrucelli
No relevant relationships to disclose
V. Saracino
No relevant relationships to disclose
G. Colucci
No relevant relationships to disclose